Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer

NCT02204033 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Neoplasms

Interventions

DRUG: 99mTc - labelled hMAb BIWA 4
DRUG: 186 Re - labelled hMAb BIWA 4
DRUG: unlabelled hMAb BIWA 4 - low dose
DRUG: unlabelled hMAb BIWA 4 - medium dose
DRUG: unlabelled hMAb BIWA 4 - high dose

Sponsor

Boehringer Ingelheim